Bharat Biotech, IVI launch Chikungunya Vaccine Phase 2/3 trial in Costa Rica

CEPI first partnered with IVI and Bharat Biotech in June 2020, providing up to USD 14.1 million for vaccine manufacturing and clinical development of the BBV87 vaccine candidate.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3klKv4K
via IFTTT